Pierre Fabre Laboratories reciben una opinión positiva del CHMP Por OBGEMSA™(vibegron) en el síndrome de vejiga hiperactiva.

Posted on by

CASTRES, Francia, 26 de abril de 2024 /PRNewswire/ — Pierre Fabre Laboratories ha anunciado que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha adoptado una opinión positiva recomendando la aprobación de OBGEMSA™ (bajo la denominación común…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.